Zobrazeno 1 - 4
of 4
pro vyhledávání: '"R. Ferri-Dessens"'
Autor:
David Coeffic, Dominique Dramais, Thomas Bachelot, Jocelyne Provencal, Agathe Bajard, Jean-Paul Guastalla, Isabelle Ray-Coquard, R. Ferri-Dessens, David Pérol
Publikováno v:
Cancer Research. 69:2099-2099
Background: Docetaxel plus capecitabine (DC) combination therapy improves both time to disease progression and overall survival over docetaxel alone in metastatic breast cancer (MBC). The aim of the ERASME-4 trials was to assess the efficacy of DC vs
Autor:
E. Luporsi, Corina Oprea, C. Platini, Dominique Dramais, D. Coefic, Thomas Bachelot, D. Perol, Jocelyne Provencal, R. Ferri-Dessens, A. Bajard
Publikováno v:
Journal of Clinical Oncology. 26:1049-1049
1049 Background: In MBC, XT improves time to progression and overall survival (OS) vs docetaxel alone (O'Shaughnessy, 2002) and first-line capecitabine + paclitaxel shows similar efficacy to epirubicin + paclitaxel (Luck, 2007). The ERASME-4 and CAPE
Autor:
F. Biville, C. Meille, Bruno Coudert, Dominique Barbolosi, Athanassios Iliadis, R. Ferri-Dessens, Laure Favier, J. Garnier
Publikováno v:
Journal of Clinical Oncology. 25:1067-1067
1067 Background: The phase I trial CAPEV CGFL 01 [ESMO, Vienne, Austria: 2004.V 52–53] aimed to find the Maximum Tolerated Dose (MTD) of i.v. Vinorelbine when associated with oral Capecitabine for three cycles of 21 days in metastatic breast cancer
Autor:
P. Paquis, Rémy Largillier, Véronique Mari, F. Van Den Bos, F. Ettore, Marc Frenay, R. Ferri-Dessens, Adel Courdi, J-M Ferrero, E. Chamorey, Antoine Italiano
Publikováno v:
Journal of Clinical Oncology. 24:10593-10593
10593 Background: Recent data report that HER2 overexpressing metastatic breast cancer patients (HER+ MBC pts) treated with trastuzumab (T) have a high rate of Brain metastasis (BM). This study aimed to evaluate the prognostic significance of BM occu